Animals
Animals, Genetically Modified
Antigens, CD
/ genetics
Antigens, Differentiation, Myelomonocytic
/ genetics
Body Composition
CD13 Antigens
/ deficiency
Coronavirus
/ immunology
Coronavirus Infections
/ genetics
Disease Susceptibility
Gastroenteritis, Transmissible, of Swine
/ genetics
Gene Knockdown Techniques
Host Microbial Interactions
Meat-Packing Industry
Phenotype
Porcine Reproductive and Respiratory Syndrome
/ genetics
Porcine respiratory and reproductive syndrome virus
/ immunology
Receptors, Cell Surface
/ deficiency
Sus scrofa
/ genetics
Swine
Transmissible gastroenteritis virus
/ immunology
Weight Gain
CRISPR/Cas9
PDCoV
PRRSV
TGEV
infectious disease
microbiology
pig
virus
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
02 09 2020
02 09 2020
Historique:
received:
21
03
2020
accepted:
04
08
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
17
9
2020
Statut:
epublish
Résumé
Porcine reproductive and respiratory syndrome virus (PRRSV) and transmissible gastroenteritis virus (TGEV) are two highly infectious and lethal viruses causing major economic losses to pig production. Here, we report generation of double-gene-knockout (DKO) pigs harboring edited knockout alleles for known receptor proteins CD163 and pAPN and show that DKO pigs are completely resistant to genotype 2 PRRSV and TGEV. We found no differences in meat-production or reproductive-performance traits between wild-type and DKO pigs, but detected increased iron in DKO muscle. Additional infection challenge experiments showed that DKO pigs exhibited decreased susceptibility to porcine deltacoronavirus (PDCoV), thus offering unprecedented in vivo evidence of pAPN as one of PDCoV receptors. Beyond showing that multiple gene edits can be combined in a livestock animal to achieve simultaneous resistance to two major viruses, our study introduces a valuable model for investigating infection mechanisms of porcine pathogenic viruses that exploit pAPN or CD163 for entry. Pig epidemics are the biggest threat to the pork industry. In 2019 alone, hundreds of billions of dollars worldwide were lost due to various pig diseases, many of them caused by viruses. The porcine reproductive and respiratory virus (PRRS virus for short), for instance, leads to reproductive disorders such as stillbirths and premature labor. Two coronaviruses – the transmissible gastroenteritis virus (or TGEV) and the porcine delta coronavirus – cause deadly diarrhea and could potentially cross over into humans. Unfortunately, there are still no safe and effective methods to prevent or control these pig illnesses, but growing disease-resistant pigs could reduce both financial and animal losses. Traditionally, breeding pigs to have a particular trait is a slow process that can take many years. But with gene editing technology, it is possible to change or remove specific genes in a single generation of animals. When viruses infect a host, they use certain proteins on the surface of the host’s cells to find their inside: the PRRS virus relies a protein called CD163, and TGEV uses pAPN. Xu, Zhou, Mu et al. used gene editing technology to delete the genes that encode the CD163 and pAPN proteins in pigs. When the animals were infected with PRRS virus or TGEV, the non-edited pigs got sick but the gene-edited animals remained healthy. Unexpectedly, pigs without CD163 and pAPN also coped better with porcine delta coronavirus infections, suggesting that CD163 and pAPN may also help this coronavirus infect cells. Finally, the gene-edited pigs reproduced and produced meat as well as the control pigs. These experiments show that gene editing can be a powerful technology for producing animals with desirable traits. The gene-edited pigs also provide new knowledge about how porcine viruses infect pigs, and may offer a starting point to breed disease-resistant animals on a larger scale.
Autres résumés
Type: plain-language-summary
(eng)
Pig epidemics are the biggest threat to the pork industry. In 2019 alone, hundreds of billions of dollars worldwide were lost due to various pig diseases, many of them caused by viruses. The porcine reproductive and respiratory virus (PRRS virus for short), for instance, leads to reproductive disorders such as stillbirths and premature labor. Two coronaviruses – the transmissible gastroenteritis virus (or TGEV) and the porcine delta coronavirus – cause deadly diarrhea and could potentially cross over into humans. Unfortunately, there are still no safe and effective methods to prevent or control these pig illnesses, but growing disease-resistant pigs could reduce both financial and animal losses. Traditionally, breeding pigs to have a particular trait is a slow process that can take many years. But with gene editing technology, it is possible to change or remove specific genes in a single generation of animals. When viruses infect a host, they use certain proteins on the surface of the host’s cells to find their inside: the PRRS virus relies a protein called CD163, and TGEV uses pAPN. Xu, Zhou, Mu et al. used gene editing technology to delete the genes that encode the CD163 and pAPN proteins in pigs. When the animals were infected with PRRS virus or TGEV, the non-edited pigs got sick but the gene-edited animals remained healthy. Unexpectedly, pigs without CD163 and pAPN also coped better with porcine delta coronavirus infections, suggesting that CD163 and pAPN may also help this coronavirus infect cells. Finally, the gene-edited pigs reproduced and produced meat as well as the control pigs. These experiments show that gene editing can be a powerful technology for producing animals with desirable traits. The gene-edited pigs also provide new knowledge about how porcine viruses infect pigs, and may offer a starting point to breed disease-resistant animals on a larger scale.
Identifiants
pubmed: 32876563
doi: 10.7554/eLife.57132
pii: 57132
pmc: PMC7467724
doi:
pii:
Substances chimiques
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
CD163 antigen
0
Receptors, Cell Surface
0
CD13 Antigens
EC 3.4.11.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Transgenic Breeding Project
ID : 2016ZX08010-004
Pays : International
Organisme : Chinese Academy of Agricultural Sciences
ID : Major Scientific Research Tasks for Scientific and Technological Innovation Project CAAS-ZDRW202006
Pays : International
Organisme : Shandong Landsee Genetics Co., Ltd.
ID : Kh17134
Pays : International
Organisme : National Natural Science Foundation of China
ID : U1704231
Pays : International
Organisme : Shenzhen Key Technology Projects
ID : JSGG20180507182028625
Pays : International
Organisme : National Transgenic Breeding Project
ID : 2016ZX08006-001
Pays : International
Organisme : National Natural Science Foundation of China
ID : 31490602
Pays : International
Informations de copyright
© 2020, Xu et al.
Déclaration de conflit d'intérêts
KX, YZ, YM, ZL, SH, YX, LF, YW, XZ, CX, JC, ZF, GX, JG, HL, SX, JL, KL No competing interests declared, CG is affiliated with Shandong Landsee Genetics Co., Ltd. The author has no financial interests to declare. HS is affiliated with Shenzhen Kingsino Technology Co., Ltd. The author has no financial interests to declare.
Références
Vet Q. 1991 Jul;13(3):121-30
pubmed: 1835211
J Virol. 2007 Jul;81(14):7371-9
pubmed: 17494075
Nature. 1992 Jun 4;357(6377):417-20
pubmed: 1350661
Emerg Infect Dis. 2009 Dec;15(12):2032-5
pubmed: 19961694
J Virol. 2018 May 29;92(12):
pubmed: 29618640
PLoS Pathog. 2017 Feb 23;13(2):e1006206
pubmed: 28231264
J Proteome Res. 2014 Dec 5;13(12):5376-90
pubmed: 25357264
Virology. 2020 Feb;541:136-140
pubmed: 32056711
Vet Microbiol. 2017 Jul;206:45-51
pubmed: 27964998
Arch Virol. 2013 Aug;158(8):1631-6
pubmed: 23494226
Transgenic Res. 2019 Feb;28(1):21-32
pubmed: 30315482
J Virol. 2010 Mar;84(6):3101-5
pubmed: 20032174
Mol Reprod Dev. 2008 May;75(5):766-76
pubmed: 18246531
Nature. 2001 Jan 11;409(6817):198-201
pubmed: 11196644
Virology. 2016 Aug;495:10-7
pubmed: 27152478
Nat Biotechnol. 2016 Jan;34(1):20-2
pubmed: 26641533
Sci Rep. 2019 Sep 12;9(1):13186
pubmed: 31515498
Virology. 2018 Apr;517:16-23
pubmed: 29502803
J Virol. 2014 Sep;88(18):10448-58
pubmed: 24965453
FEBS Lett. 2002 Aug 28;526(1-3):93-6
pubmed: 12208511
J Virol. 2012 Apr;86(7):3995-4008
pubmed: 22278237
Virus Res. 2009 Mar;140(1-2):161-71
pubmed: 19111584
Antiviral Res. 2018 Mar;151:63-70
pubmed: 29337166
Vet Res Commun. 2010 Oct;34(7):607-17
pubmed: 20676761
Sci Rep. 2015 Sep 18;5:14253
pubmed: 26381350
Vet Microbiol. 2003 Sep 1;95(3):175-86
pubmed: 12935745
Int J Biol Sci. 2019 Jan 1;15(2):481-492
pubmed: 30745836
Cell. 1989 May 19;57(4):537-47
pubmed: 2720781
Sci Rep. 2017 Oct 11;7(1):12940
pubmed: 29021532
J Exp Med. 1986 Dec 1;164(6):1862-75
pubmed: 3783087
Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5135-E5143
pubmed: 29760102
J Gen Virol. 2008 Dec;89(Pt 12):2943-2953
pubmed: 19008379
J Virol. 1998 Jan;72(1):527-34
pubmed: 9420255
Emerg Microbes Infect. 2018 Apr 11;7(1):65
pubmed: 29636467
J Virol. 2017 Jan 18;91(3):
pubmed: 27881657
J Virol. 2017 Jan 3;91(2):
pubmed: 27847356
Front Immunol. 2019 Aug 08;10:1846
pubmed: 31440241
BMC Dev Biol. 2006 Aug 09;6:41
pubmed: 16899119
Oncotarget. 2017 Jun 6;8(23):37751-37760
pubmed: 28465483
Am J Vet Res. 1997 May;58(5):488-91
pubmed: 9140556
Reproduction. 2003 Apr;125(4):535-42
pubmed: 12683924
Cell Mol Life Sci. 2015 Mar;72(6):1175-84
pubmed: 25274063
Vet Microbiol. 2016 Nov 30;196:98-106
pubmed: 27939164
Emerg Infect Dis. 2014 Sep;20(9):1594-5
pubmed: 25153521
PLoS Pathog. 2012;8(8):e1002859
pubmed: 22876187